文献速递药物不良反应与药物警戒特殊人群用药

第二代抗精神病药相关代谢综合征的全基因组关联研究

Genome-wide associations with metabolic syndrome among UK Biobank participants reporting use of second-generation antipsychotics.
PubMed 文献 · Pharmacotherapy · 2025-08-05

本研究基于英国生物银行1318名报告使用第二代抗精神病药(SGA)的参与者,采用NCEP-ATP III标准定义SGA相关代谢综合征(SGA-MetS),进行全基因组关联研究(GWAS)和基于基因的分析。GWAS在15号染色体发现提示性关联,rs12914956(CHD2)与SGA-MetS风险增加相关(OR=1.73,95%CI=1.4-2.4,p=3.6×10-7)。基于基因的分析发现RBFOX1、PTPRD、CSMD1和CHD2与SGA-MetS显著相关。BMI多基因风险评分(PGS-BMI)与SGA-MetS风险增加相关(β=0.23,p=6.8×10-5),提示遗传易感性高BMI可能增加SGA-MetS风险。

要点

  • CHD2基因变异rs12914956与SGA相关代谢综合征风险增加相关(OR=1.73)。
  • RBFOX1、PTPRD、CSMD1和CHD2基因与SGA相关代谢综合征显著相关。
  • BMI多基因风险评分与SGA相关代谢综合征风险增加相关(β=0.23)。

核心结论

  • 基于基因的分析发现与SGA-MetS显著相关的基因,这些基因先前与肥胖和代谢性状相关。
  • PGS-BMI与MetS相关,提示遗传倾向的高BMI可能增加SGA-MetS风险。

研究设计与样本

  • 研究使用英国生物银行1318名报告使用SGA的参与者的横截面数据。
  • SGA-MetS定义为满足NCEP-ATP III五项标准中的三项或以上。
  • 进行了全基因组关联研究(GWAS)和基于基因的分析。
  • 使用2,100,302个变异计算BMI多基因风险评分(PGS-BMI),并用逻辑回归检验其与SGA-MetS的关联。

主要发现

  • GWAS在15号染色体发现提示性关联(p < 1×10-5)。
  • CHD2变异rs12914956与SGA-MetS风险增加相关(OR=1.73,95%CI=1.4-2.4,p=3.6×10-7)。
  • 基于基因的分析发现RBFOX1(p=4.85×10-7)、PTPRD(p=7.6×10-7)、CSMD1(p=2.2×10-6)和CHD2(p=1.3×10-6)与SGA-MetS显著相关。
  • PGS-BMI与SGA-MetS风险增加相关(β=0.23,p=6.8×10-5),模型调整了年龄、性别、体力活动、酒精消费、抗抑郁药、精神分裂症诊断和祖先主成分。

关键数值与推荐

  • SGA-MetS病例定义为满足NCEP-ATP III五项标准中的三项或以上。
  • GWAS提示性关联阈值为p < 1×10-5。
  • CHD2变异rs12914956的OR=1.73(95%CI=1.4-2.4),p=3.6×10-7。
  • 基于基因分析的显著基因p值:RBFOX1 p=4.85×10-7,PTPRD p=7.6×10-7,CSMD1 p=2.2×10-6,CHD2 p=1.3×10-6。
  • PGS-BMI的β=0.23,p=6.8×10-5。

临床怎么用

  • 对于使用SGA的患者,可考虑评估代谢综合征风险,尤其是有肥胖遗传倾向者。
  • CHD2等基因变异可能作为SGA-MetS风险预警的潜在标记,但需进一步验证。
  • BMI多基因风险评分可能有助于识别SGA-MetS高风险患者,指导监测和预防。

局限性

  • 研究为横截面设计,无法推断因果关系。
  • 样本量有限(1318人),需在更大、更多样化人群中重复验证。
  • SGA-MetS定义基于NCEP-ATP III标准,可能受限于数据可得性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Second-generation antipsychotic (SGA) medications are frequently prescribed for mental health conditions; however, they are associated with an increased risk of metabolic syndrome (MetS). We aimed to identify genetic associations of SGA-associated MetS (SGA-MetS) using genome-wide approaches within the UK Biobank. We also set out to evaluate if genetically predicted obesity is associated with an increased risk of SGA-MetS. METHODS: We defined SGA-MetS based on the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria using cross-sectional data from 1318 UK Biobank participants who reported being on an SGA medication. An SGA-MetS case was defined as meeting three or more of the five NCEP-ATP III criteria. We performed a genome-wide association study (GWAS) and gene-based analysis to identify significant variants and gene associations. We computed the polygenic risk score (PGS) for body mass index (BMI) using 2,100,302 variants validated for obesity and metabolic traits from imputed single-nucleotide polymorphism (SNP) data. We tested the association of PGS-BMI with SGA-MetS using logistic regression. RESULTS: GWAS identified suggestive associations (p < 1 × 10-5) on chromosome 15. The variant rs12914956 in CHD2 was associated with increased risk of SGA (odds ratio (OR) = 1.73, 95% confidence interval (CI) = 1.4-2.4, p = 3.6 × 10-7). The gene-based analysis identified significant gene associations with RBFOX1 (p = 4.85 × 10-7), PTPRD (p = 7.6 × 10-7), CSMD1 (p = 2.2 × 10-6), and CHD2 (p = 1.3 × 10-6). The PGS-BMI (β = 0.23, p = 6.8 × 10-5), was associated with increased MetS in a model adjusted for age, sex, physical activity, alcohol consumption, antidepressant medications, schizophrenia diagnosis, and principal components of ancestry. CONCLUSION: Using a gene-based analysis, we identified significant gene associations with SGA-MetS that have been previously associated with obesity and metabolic traits. The PGS-BMI was associated with MetS, suggesting that a genetic predisposition to a higher BMI may increase the risk of SGA-MetS. Future research should replicate the findings in a larger dataset with more diverse populations.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Rouby NE, Owusu-Obeng A, Preuss M, et al. Genome-wide associations with metabolic syndrome among UK Biobank participants reporting use of second-generation antipsychotics. Pharmacotherapy. 2025. PMID: 40762455. doi:10.1002/phar.70041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。